REPL Stock Risk & Deep Value Analysis
Replimune Group Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About REPL Stock
We analyzed Replimune Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran REPL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
REPL Risk Analysis & Red Flags
What Could Go Wrong
RP1, Replimune's lead candidate, could face unexpected regulatory hurdles leading to a BLA rejection or significant delays in approval. Alternatively, a competitor like BioNTech could launch a product with superior clinical data, severely limiting RP1's market penetration and Replimune's ability to achieve profitability, leading to a substantial stock price drop and potential need for dilutive capital raises.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Currently pre-revenue with significant negative free cash flow, relying heavily on future approvals.
- ⚠
High concentration of risk on a single lead asset (RP1) for near-term revenue generation.
- ⚠
Competitive landscape includes established players (Amgen) and rapidly advancing rivals (BioNTech with strong ORR data).
Upcoming Risk Events
- 📅
Negative or delayed RP1 BLA review by regulatory authorities
- 📅
Clinical trial failures or unexpected safety signals for RP1 or other pipeline assets
- 📅
Key competitor product launches with superior efficacy or safety profiles
When to Reconsider
- 🚪
FDA issues a Complete Response Letter (CRL) for RP1's BLA or outright rejection.
- 🚪
Cash burn rate significantly accelerates beyond current projections without corresponding revenue growth.
- 🚪
A competitor announces Phase 3 data in a directly overlapping indication with significantly superior efficacy or safety.
Unlock REPL Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Replimune Group Inc (REPL) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
479
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Visit Replimune Group Inc WebsiteInvestment Thesis
Replimune is a high-potential biotechnology company poised to disrupt the oncology market with its oncolytic immunotherapy platform, particularly its lead candidate RP1. Recent positive Phase 3 data and BLA submission on track for H2 2026 position the company for significant re-rating upon approval, leveraging its unique mechanism for combination therapies and strong partnerships to capture substantial market share in areas of high unmet medical need like anti-PD1 failed melanoma. Its robust balance sheet provides a strong runway to navigate through the approval process.
Is REPL Stock Undervalued?
Unlock the full AI analysis for REPL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
REPL Price Targets & Strategy
12-Month Target
$25.00
Bull Case
$30.00
Bear Case
$5.00
Valuation Basis
Based on an estimated 1.5x peak sales multiple for RP1 in initial indications, discounted for pre-approval clinical and regulatory risk.
Entry Strategy
Dollar-cost average between $9-$11, seeking entry on pullbacks to strengthen average cost basis.
Exit Strategy
Take 50% profit at $25, re-evaluate upon approval, stop loss at $7 if key clinical milestones are missed or price falls significantly.
Portfolio Allocation
7-15% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is REPL Financially Healthy?
Profitability
Return on Equity
-96.24%
EPS
$-3.47
Balance Sheet
Current Ratio
6.31
Quick Ratio
6.15
Debt/Equity
0.29
Total Debt
$76.32M
Cash & Equivalents
$323.64M
Cash Flow
EBITDA
-$312.95M
Does REPL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily derived from its proprietary technology and clinical data, which is protected by patents. The strategic partnership further strengthens its position. Durability will depend on continued clinical success, expansion into multiple indications, and the ability to fend off emerging competition with alternative technologies.
Moat Erosion Risks
- •Patent challenges or expiry reducing intellectual property protection
- •Emergence of superior oncolytic virus technologies or competing treatment modalities
- •Failure to achieve regulatory approval or market adoption for lead product.
REPL Competitive Moat Analysis
Sign up to see competitive advantages
REPL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by recent positive clinical data and on-track regulatory filings.
Institutional Sentiment
Positive, evidenced by 78.4% institutional ownership and strong analyst consensus (10 Buy, 1 Hold) with recent price target increases (HC Wainwright to $28).
Insider Activity (Form 4)
No Form 4 filings reporting insider buys or sells in the last 90 days (Jan 8 - Apr 8, 2026).
Options Flow
Normal options activity (no specific data provided in research brief).
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
Historically, clinical-stage biotechs like Replimune experience significant stock price volatility based on clinical trial news, regulatory updates, and cash runway updates, rather than quarterly earnings which typically report losses.
Key Metrics to Watch
Competitive Position
Top Competitor
BioNTech (BNT111)
Market Share Trend
Pre-commercial, currently seeking to establish market share in the oncolytic virus niche, particularly for anti-PD1 failed melanoma.
Valuation vs Peers
Trading at N/A for traditional P/E or P/S due to lack of revenue. P/B of 1.7x is below the biotech sector median of 3.2x, suggesting potential relative undervaluation given its advanced clinical pipeline.
Competitive Advantages
- •Unique mechanism of action for RP1 (oncolytic immunotherapy designed for combination therapy)
- •Strategic partnership with Bristol Myers Squibb providing validation and potential co-development/commercialization support
- •Positive Phase 3 clinical data for RP1 in a challenging patient population (anti-PD1 failed melanoma)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive REPL Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (May 12, 2026)
- •Full RP1 Phase 3 IGNYTE data presentation at a major oncology conference (e.g., ASCO, ESMO)
- •RP1 Biologics License Application (BLA) submission to FDA (H2 2026)
Medium-Term (6-18 months)
- •RP1 regulatory review progress by FDA (H2 2026 - H2 2027)
- •Potential RP1 FDA approval decision for anti-PD1 failed melanoma (H2 2027)
- •Data readouts from expanded RP1 trials (e.g., neoadjuvant melanoma)
Long-Term (18+ months)
- •RP1 commercial launch and label expansion into additional indications
- •Pipeline progression of other oncolytic virus candidates
- •New strategic partnerships or collaborations
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for REPL?
- ✓
Acceleration in RP1 regulatory review process or positive FDA advisory committee meeting outcomes
- ✓
Expansion of RP1's clinical development into new, high-value indications with compelling data
- ✓
Announcement of additional strategic partnerships or collaborations for pipeline assets.
Bull Case Analysis
See what could go right with Premium
Competing with REPL
See how Replimune Group Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Replimune Group Inc REPL | — | 8.7 | — | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Replimune Group Inc Makes Money
Replimune is a clinical-stage biotechnology company focused on developing and commercializing a novel class of cancer treatments called oncolytic immunotherapies. These therapies use modified viruses to directly kill cancer cells and activate the patient's immune system to fight the tumor. The company currently has no revenue and generates losses as it invests heavily in research and development to bring its drug candidates, such as RP1, through rigorous clinical trials and secure regulatory approvals from health authorities like the FDA. Upon approval, Replimune aims to generate revenue through the direct sale of its proprietary drugs or via licensing and collaboration agreements with larger pharmaceutical partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Replimune Group Inc (REPL)?
As of April 8, 2026, Replimune Group Inc has a DVR Score of 8.7 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Replimune Group Inc use?
REPL is the ticker symbol for Replimune Group Inc. The company trades on the NMS.
What is the risk level for REPL stock?
Our analysis rates Replimune Group Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Replimune Group Inc's revenue growing?
Replimune Group Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is REPL stock profitable?
Replimune Group Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the REPL DVR analysis updated?
Our AI-powered analysis of Replimune Group Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for REPL (Replimune Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.